AtaiBeckley Inc. 4

Insider Robert Hershberg had all of his AtaiBeckley Inc. stock options (covering 741,089 shares total) cancelled and cashed out at the $6.75 merger price plus CVRs in connection with Eli Lilly’s acquisition.

On September 11, 2026, in connection with the acquisition of AtaiBeckley Inc. by Eli Lilly and Company, all of Robert Hershberg’s outstanding AtaiBeckley stock options were automatically cancelled and converted into a cash payment plus contingent value rights (CVRs), rather than being exercised or sold on the open market. Each option grant, covering 48,858; 404,869; 62,394; 103,000; and 121,968 shares of common stock at exercise prices of $1.35, $1.35, $1.35, $4.48, and $4.50 respectively, was converted into the right to receive cash equal to the number of option shares multiplied by the excess of $6.75 over the option exercise price, plus one CVR per underlying share that may pay up to an additional $2.50 in cash upon future milestone achievements. The Form 4 shows these option positions going to zero and the corresponding underlying common stock entries also at zero, reflecting the termination of equity interests as the company became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036379

Alert Tier

6